atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts
Portfolio Pulse from
Analysts at Jefferies have reiterated a 'Buy' rating for atai Life Sciences, predicting a significant share price increase by 2025 due to upcoming Phase 2 and 3 trial data readouts. They have set a price target of $5, suggesting a potential upside of 242%.
November 14, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies analysts have reiterated a 'Buy' rating for atai Life Sciences, with a $5 price target, driven by expected positive trial data readouts in 2025.
The reiteration of a 'Buy' rating and a significant price target increase by Jefferies is likely to positively impact ATAI's stock price in the short term. The anticipation of positive trial data readouts in 2025 adds to the bullish sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100